NIH-funded research R01 grant

Understanding how COVID-19 affects the sense of smell and the brain in mice

Official title: Mechanisms of anosmia and brain infection in a genetic mouse model of COVID-19

Funded at Icahn School of Medicine at Mount Sinai · NIH-10994608 · Data updated 2026-11-12

This study is looking at how COVID-19 can cause loss of smell and possibly affect the brain by using specially modified mice, which could help us understand why some people experience these symptoms and what it means for their health in the long run.

More COVID-19 research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionIcahn School of Medicine at Mount Sinai
NIH-funded
Lab location1 site (New York, United States)
Project startDecember 5, 2023
Project endNovember 30, 2028
Funding year2025
Award (this year)$691,863
NIH project number5R01DC020980-02
Project IDNIH-10994608 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals who have experienced anosmia or neurological symptoms following COVID-19 infection.

Less likely to help

Patients who have not been infected with COVID-19 or do not exhibit symptoms related to anosmia or neurological issues may not benefit from this research.

What this research studies

This research investigates how COVID-19 leads to loss of smell (anosmia) and potential brain infection using a genetically modified mouse model. The study focuses on the olfactory epithelium, which is believed to be a key entry point for the virus, and examines how the virus affects different cell types in the brain. By using mice that express human ACE2, the research aims to identify the mechanisms behind anosmia and the neurological impacts of COVID-19. This could provide insights into the long-term effects of the virus on patients.

Why it matters

Potential benefit: If successful, this research could lead to better understanding and treatment options for patients experiencing long-term loss of smell and neurological symptoms after COVID-19.

How similar studies have gone: Other research has shown promising results in understanding the neurological impacts of COVID-19, but this specific approach using genetically modified mice is relatively novel.

Where this research is happening

  • Icahn School of Medicine at Mount Sinai
    New York, United States
    Active

Researchers

  • Principal investigator: Millar, Sarah E. — Icahn School of Medicine at Mount Sinai
  • Study coordinator: Millar, Sarah E.

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.